Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375220 | 0.91 | GPR84 (0.41) | GPR84DRD2SLC6A4POLBALKBH5 | |
| SCHEMBL820521 | 0.91 | GPR84 (0.41) | GPR84DRD2SLC6A4POLBALKBH5 | |
| SCHEMBL375340 | 0.87 | GPR84 (0.37) | GPR84DRD2SLC6A4POLBHTR2A | |
| SCHEMBL819282 | 0.86 | POLB (0.52) | DRD2POLBALDH1A1KMT2ADRD4 | |
| SCHEMBL823070 | 0.86 | POLB (0.52) | DRD2POLBALDH1A1KMT2ADRD4 | |
| SCHEMBL2453968 | 0.83 | HTR1B (0.43) | GPR84DRD2HTR2AHTR7BRD3 | |
| SCHEMBL12037508 | 0.83 | HTR1B (0.43) | GPR84DRD2HTR2AHTR7BRD3 | |
| SCHEMBL819716 | 0.79 | GPR119 (0.35) | BRD3 | |
| SCHEMBL15512736 | 0.78 | GPR84 (0.45) | GPR84DRD2SLC6A4ALKBH5FTO | |
| SCHEMBL2631835 | 0.77 | TDO2 (0.35) | DRD2SLC6A4ALDH1A1HTR2ATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2409984-A1 | Dimeric IAP Antagonists | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2409984-A1 | Dimeric IAP Antagonists | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | GPR84 3704/4885DRD2 4800/4885SLC6A4 4756/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | GPR84 3290/4885DRD2 4871/4885SLC6A4 4770/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | GPR84 2656/4885DRD2 4515/4885SLC6A4 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.